Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Post by whoa_rimcheeseon Jun 15, 2014 6:12pm
283 Views
Post# 22661879

Another flawed theory….

Another flawed theory….There has been a theory proposed that the company announces a private placement, then releases some positive news on the research front thereby allowing for a window of opportunity for the placement holders to unload at a big gain - only to then have the price drift downwards. Just looking at the most recent placement, that theory is flawed. The placement in early November was right around the trading price of the time, and yes, after the placement announcement, the price did indeed climb nicely. HOWEVER, the positive news about the mice remaining cancer free was actually in advance of the placement in mid-October - unfortunately, the price didn't move much - volumes were low as this was not as followed as a stock, clearly. Thus, what this tells me is the company was probably hoping to do the placement at a higher price, but the price didn't respond as management had hoped. Thus, one could argue that management was hoping against dilution. Considering how much insiders hold, I think that theory is more probable than the "pump and dump" stuff that some have brought forth. Just my thoughts.
Bullboard Posts